These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32206993)

  • 1. Baseline Factors Associated with Mortality in Patients Who Engaged in Buprenorphine Treatment for Opioid Use Disorder: a Cohort Study.
    Fine DR; Yu L; Triant VA; Baggett TP; Metlay JP
    J Gen Intern Med; 2020 Aug; 35(8):2375-2382. PubMed ID: 32206993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
    Fine DR; Lewis E; Weinstock K; Wright J; Gaeta JM; Baggett TP
    JAMA Netw Open; 2021 Mar; 4(3):e210477. PubMed ID: 33662132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
    Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
    Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
    Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
    Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
    Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
    Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
    Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
    JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.
    Glanz JM; Binswanger IA; Clarke CL; Nguyen AP; Ford MA; Ray GT; Xu S; Hechter RC; Yarborough BJH; Roblin DW; Ahmedani B; Boscarino JA; Andrade SE; Rosa CL; Campbell CI
    Addiction; 2023 Jan; 118(1):97-107. PubMed ID: 35815386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries.
    Samples H; Nowels MA; Williams AR; Olfson M; Crystal S
    Am J Prev Med; 2023 Jul; 65(1):19-29. PubMed ID: 36906496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Buprenorphine for Opioid Use Disorder and Mortality Risk.
    Vakkalanka P; Lund BC; Arndt S; Field W; Charlton M; Ward MM; Carnahan RM
    Am J Prev Med; 2021 Sep; 61(3):418-427. PubMed ID: 34023160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
    Samples H; Williams AR; Crystal S; Olfson M
    J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality.
    Lei F; Lofwall MR; McAninch J; Adatorwovor R; Slade E; Freeman PR; Moga DC; Dasgupta N; Walsh SL; Vickers-Smith R; Slavova S
    J Addict Med; 2024 May-Jun 01; 18(3):319-326. PubMed ID: 38598300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.
    Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
    Addiction; 2022 Jun; 117(6):1683-1691. PubMed ID: 35072314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk.
    Tardelli V; Xu KY; Bisaga A; Levin FR; Fidalgo TM; Grucza RA
    BMJ Ment Health; 2023 Jul; 26(1):. PubMed ID: 37500184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
    Nguyen B; Zhao C; Bailly E; Chi W
    J Gen Intern Med; 2024 Jan; 39(1):95-102. PubMed ID: 37670069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.
    Bech AB; Clausen T; Waal H; Šaltytė Benth J; Skeie I
    BMC Health Serv Res; 2019 Jul; 19(1):440. PubMed ID: 31266495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.